Swiss Group For Clinical Cancer Research

Recent papers from Swiss Group For Clinical Cancer Research

1. The immunophenotypic landscape of newly diagnosed acute myeloid leukemia: Associations with genotype and outcomesiScience · 2026
2. Sex, Timing, and Outcomes of Curative-Intent ImmunotherapyJAMA Network Open · 2026
3. Validation of the advanced‐stage Hodgkin lymphoma international prognostic index (A‐HIPI) in the GHSG HD21 trialHemaSphere · 2026
4. Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE TrialJournal of Clinical Oncology · 2026
5. Impact of Postoperative Antithrombotic Treatment on Patency and Survival After Open Posterior Popliteal Artery Aneurysm Repair: A Multicenter Retrospective Cohort Analysis from the PARADE StudyJournal of Clinical Medicine · 2026
6. Extracellular vesicles as prognostic biomarkers: results of a neoadjuvant chemoimmunotherapy clinical trial in stage IIIA (N2) non-small-cell lung cancer (SAKK 16/14)Frontiers in Immunology · 2026
7. CEBP and ZEB2 alterations define three distinct subtypes of B‐cell acute lymphoblastic leukemiaHemaSphere · 2026
8. Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancerAnnals of Oncology · 2026
9. Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19Journal of Clinical Oncology · 2026
10. NoLEEta: No chemotherapy in intermediate-risk HR+ HER2− early breast cancer treated with ribociclib in the adjuvant setting—A non-inferiority phase III trial.Journal of Clinical Oncology · 2026
11. Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors: A multicenter phase Ib/IIa trial with expansion cohorts in melanoma and soft tissue sarcoma patients (SAKK 66/17).Journal of Clinical Oncology · 2026
12. Prevalence of symptomatic skeletal events (SSE) with reduced denosumab (Dmab) dose density (every 12 weeks versus every 4 weeks): A randomized phase III non-inferiority trial SAKK 96/12 REDUSE.Journal of Clinical Oncology · 2026
13. Intravesical recombinant BCG combined with chemo-immunotherapy (chemo-IO) as perioperative therapy for patients with muscle-invasive bladder cancer (MIBC): Primary analysis of SAKK 06/19.Journal of Clinical Oncology · 2026
14. A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma—SAKK 66/18 TrialCancers · 2026
15. 275P 15-year incidence of invasive local, regional or contralateral events as first subsequent breast cancer event among HR+ premenopausal patients in SOFT and TEXTESMO Open · 2026
16. 24-week home-based walking program in the early adjuvant setting in breast cancer patients who receive aromatase inhibitor endocrine therapy: lessons learned from the SAKK 95/17 WISE prospective, randomized, multicenter trial.2026
17. Prognostic value of measurable residual disease in high‐risk MDS after intensive chemotherapy in HOVON‐SAKK studiesHemaSphere · 2026
18. Abstract 106: Integrated plasma multi-omics profiling identifies circulating predictive biomarkers and biological pathways associated with treatment response in NSCLC.Cancer Research · 2026
19. Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy versus liposomal cytarabine and daunorubicinHaematologica · 2026
20. Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14)European Urology Oncology · 2026